Corporate Profile

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing ZerenexTM (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. ZerenexTM has completed a U.S.-based Phase 3 clinical program for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage... More >>
Featured Report
Download Documentation 2012 10-K

Stock Quote
KERX (Common)
ExchangeNASDAQ (US Dollar)
Price$8.05
Change (%) Stock is Up 0.11 (1.39%)
Volume1,392,027
Data as of 05/21/13 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Receive E-mail AlertsE-mail Alert Icon
Recent News
DateTitle 
05/07/13Keryx Biopharmaceuticals, Inc. Announces First Quarter 2013 Financial ResultsPrinter Friendly Version
05/06/13Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2013 Financial ResultsPrinter Friendly Version
03/14/13Keryx Biopharmaceuticals to Present at the 25th Annual ROTH ConferencePrinter Friendly Version
03/13/13Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical AffairsPrinter Friendly Version
Upcoming Events
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.


Copyright © 2013 by Keryx Biopharmaceuticals, Inc.
Update Notice | Disclaimer | Contact Us